Thursday 7 May, 2026
Introduction: Ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) are serious infectious complications in hospitalized and critically ill patients, contributing to…
Read moreAbstracts
Quantitative Systems Immunology: Unraveling Human CD4+ T-Lymphocyte Kinetics, Tissue Distribution, and Aging Using Mechanistic Modeling
Thursday 7 May, 2026
Introduction CD4+ T lymphocytes represent a central component of the human adaptive immune system, coordinating and regulating immune responses throughout…
Read moreImpact of PK/PD indices on target attainment of vancomycin therapy in critically ill children: back to the drawing board
Thursday 7 May, 2026
Introduction Vancomycin is a moderately plasma protein-bound glycopeptide antibiotic used to treat severe infections caused by Gram-positive bacteria [1]. Sub-…
Read moreBUILDING AN OPEN-SOURCE SUB-SAHARAN AFRICAN PBPK POPULATION: INTEGRATING ANATOMICAL, PHYSIOLOGICAL, AND ENZYMATIC VARIABILITY
Thursday 7 May, 2026
Introduction: Sub‑Saharan Africa (SSA) faces an outsized burden of infectious diseases but continues to be underrepresented in pharmacokinetic (PK) studies….
Read moreHomoscedastic Uncertainty Weighting-Enhanced Multi-Task Multi-Granularity NER for Pharmacokinetic Parameters
Thursday 7 May, 2026
Objectives: The exponential growth of pharmacological information in unstructured sources such as scientific publications and clinical trial reports presents a…
Read moreConcentration-QTc (C-QTc) analysis using PK/PD modeling to evaluate time- and exposure-dependent drug-induced QT interval prolongation
Thursday 7 May, 2026
Introduction Drug-induced QT prolongation is a serious side effect where certain medications delay heart muscle recharging, risking a fatal, rapid,…
Read morePOPULATION PHARMACOKINETICS, ANTIDRUG ANTIBODIES AND EXPOSURE–RESPONSE OF LOTIVIBART (LVB, VH3810109, N6LS) IN VIROLOGICALLY SUPPRESSED ADULTS LIVING WITH HIV FROM THE PHASE 2B EMBRACE STUDY
Thursday 7 May, 2026
Introduction: Lotivibart (LVB, VH3810109, N6LS) is a broadly neutralizing antibody targeting the CD4-binding site of the HIV-1 envelope, currently being…
Read moreCONCENTRATION-QTC ANALYSIS OF TOVORAFENIB IN PATIENTS WITH RAF-ALTERED, RELAPSED/REFRACTORY PEDIATRIC LOW-GRADE GLIOMA, ADVANCED SOLID TUMORS AND MELANOMA
Thursday 7 May, 2026
Introduction: Genetic alterations and dysregulation of the mitogen-activated protein kinase (MAPK) pathway have been found in many different types of…
Read morePEDIATRIC PBPK MODELING TO SUPPORT THERAPEUTIC DRUG MONITORING OF METHOTREXATE
Thursday 7 May, 2026
Background and Objectives: The antifolate agent methotrexate (MTX) is a cornerstone for chronic inflammatory diseases and chemotherapy in adult and…
Read morePHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) MODELING OF GALNAC-SIRNA GSK4532990 HSD17B13 KNOCKDOWN: INFORMING SKYLINE PHASE 2 PRIMARY ENDPOINTS AND OPTIMAL DOSING IN MASH
Thursday 7 May, 2026
Introduction: Loss-of-function (LOF) gene mutations in hydroxysteroid 17-beta-dehydrogenase-13 (HSD17B13) are associated with reduced risk of steatotic liver disease including metabolic…
Read more